MREO
Mereo BioPharma Group plc NASDAQ Listed Apr 24, 2019$0.24
Mkt Cap $38.3M
52w Low $0.20
1.4% of range
52w High $3.05
50d MA $0.34
200d MA $1.21
P/E (TTM)
-1.0x
EV/EBITDA
-0.7x
P/B
1.0x
Debt/Equity
0.0x
ROE
-102.4%
P/FCF
-2.1x
RSI (14)
—
ATR (14)
—
Beta
0.38
50d MA
$0.34
200d MA
$1.21
Avg Volume
2.3M
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
One Cavendish Place · London W1G 0QF · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.01 | -0.01 | +0.0% | 0.36 | -3.5% | -5.2% | +0.2% | -1.9% | +4.1% | -3.1% | — |
| Nov 10, 2025 | AMC | -0.01 | -0.01 | -20.4% | 1.77 | +1.1% | +5.6% | -1.6% | -3.3% | +0.0% | -0.6% | — |
| Aug 12, 2025 | AMC | -0.01 | -0.02 | -100.0% | 1.66 | +0.0% | +4.2% | -1.2% | +1.8% | -3.4% | -2.4% | — |
| May 13, 2025 | AMC | -0.01 | -0.02 | -100.0% | 2.32 | +0.9% | -0.4% | -5.6% | +2.8% | +2.2% | +0.4% | — |
| Mar 26, 2025 | AMC | -0.02 | -0.01 | +50.0% | 2.37 | +13.9% | +1.7% | -4.6% | -2.2% | -3.6% | +9.2% | — |
| Nov 12, 2024 | AMC | -1.36 | -7.69 | -465.4% | 4.10 | -1.5% | -1.2% | -5.7% | -7.6% | -5.7% | +4.8% | — |
| Aug 13, 2024 | AMC | -0.78 | -0.02 | +97.4% | 3.76 | +0.0% | +5.1% | +3.3% | +6.1% | +3.2% | -0.7% | — |
| May 15, 2024 | AMC | — | -0.01 | — | 3.17 | -0.6% | +3.2% | -2.1% | +1.9% | -6.7% | -1.6% | — |
| Mar 27, 2024 | AMC | -0.02 | -0.01 | +44.5% | 3.00 | +3.3% | +10.0% | +3.3% | -0.9% | +0.9% | -4.4% | — |
| Nov 17, 2023 | AMC | — | -0.01 | — | 2.08 | +1.0% | +5.3% | +4.1% | -8.6% | +3.1% | -8.4% | — |
| Sep 7, 2023 | AMC | -0.02 | -0.03 | -37.0% | 1.43 | -0.7% | -1.4% | -2.1% | +1.4% | +2.9% | +11.1% | — |
| Jun 27, 2023 | AMC | — | -0.01 | — | 1.20 | +0.0% | +5.8% | +0.0% | +3.9% | -2.3% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | JP Morgan | Downgrade | Overweight → Neutral | — | $0.34 | $0.33 | -3.5% | +0.2% | -1.9% | +4.1% | -3.1% | -2.9% |
| Jan 16 | BTIG | Maintains | Buy → Buy | — | $0.67 | $0.71 | +5.9% | -4.5% | -11.7% | -6.2% | +0.4% | -1.0% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $0.57 | $0.55 | -3.7% | +16.3% | +8.6% | -6.4% | -4.5% | -11.7% |
| Dec 30 | Jefferies | Downgrade | Buy → Hold | — | $0.29 | $0.30 | +5.5% | +29.8% | +12.5% | +22.5% | -5.8% | -21.1% |
| Dec 29 | BTIG | Maintains | Buy → Buy | — | $2.31 | $0.25 | -89.2% | -87.6% | +29.8% | +12.5% | +22.5% | -5.8% |
| Dec 29 | LifeSci Capital | Downgrade | Outperform → Market Perform | — | $2.31 | $0.25 | -89.2% | -87.6% | +29.8% | +12.5% | +22.5% | -5.8% |
| Dec 22 | Needham | Maintains | Buy → Buy | — | $2.00 | $2.09 | +4.5% | +14.5% | +0.0% | +0.4% | +0.4% | -87.6% |
| Dec 18 | BTIG | Maintains | Buy → Buy | — | $1.92 | $1.94 | +1.0% | +0.0% | +4.2% | +14.5% | +0.0% | +0.4% |
| Aug 25 | JP Morgan | Maintains | Overweight → Overweight | — | $1.70 | $1.74 | +2.4% | +2.4% | +1.1% | +0.0% | -0.6% | -2.3% |
| Jul 10 | Needham | Maintains | Buy → Buy | — | $2.94 | $2.03 | -31.0% | -42.5% | -4.7% | +6.8% | -0.6% | +2.3% |
| May 13 | Needham | Maintains | Buy → Buy | — | $2.50 | $2.50 | +0.0% | -7.2% | -0.4% | -5.6% | +2.8% | +2.2% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $1.76 | $1.70 | -3.4% | +8.0% | -3.7% | +6.6% | -2.6% | +5.3% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $2.35 | $2.35 | +0.0% | +0.9% | +1.7% | -4.6% | -2.2% | -3.6% |
| Mar 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.63 | $2.61 | -0.8% | -3.8% | +2.0% | -0.8% | -7.0% | +4.6% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $3.55 | $3.30 | -7.0% | -5.9% | -8.4% | -1.0% | -4.3% | -1.4% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $3.45 | $3.40 | -1.4% | -1.4% | -2.6% | -0.6% | +1.8% | +1.2% |
| Nov 12 | Needham | Maintains | Buy → Buy | — | $4.28 | $4.16 | -2.8% | -4.2% | -1.2% | -5.7% | -7.6% | -5.7% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.11 | $4.15 | +1.0% | +1.5% | +2.9% | +2.6% | +0.0% | -3.4% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.28 | $4.26 | -0.5% | +5.1% | -12.2% | +6.8% | +1.4% | -0.7% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $3.72 | $3.73 | +0.3% | +1.1% | +5.1% | +3.3% | +6.1% | +3.2% |
| Jul 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.88 | $3.86 | -0.5% | +2.6% | +3.8% | -4.4% | +3.3% | +2.0% |
| Jun 20 | Leerink Partners | Maintains | Outperform → Outperform | — | $3.98 | $4.02 | +1.0% | -2.3% | +2.3% | -5.5% | -6.9% | -0.3% |
| Jun 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.52 | $3.94 | +11.9% | +8.8% | +4.2% | +6.5% | +0.0% | -6.4% |
| Jun 12 | Needham | Maintains | Buy → Buy | — | $3.52 | $3.94 | +11.9% | +8.8% | +4.2% | +6.5% | +0.0% | -6.4% |
| May 16 | Needham | Maintains | Buy → Buy | — | $3.17 | $3.15 | -0.6% | +3.2% | -2.1% | +1.9% | -6.7% | -1.6% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.17 | $3.15 | -0.6% | +3.2% | -2.1% | +1.9% | -6.7% | -1.6% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $3.13 | $3.03 | -3.2% | -6.1% | -6.8% | -0.7% | -1.8% | +0.7% |
| Mar 28 | Needham | Maintains | Buy → Buy | — | $3.00 | $3.10 | +3.3% | +10.0% | +3.3% | -0.9% | +0.9% | -4.4% |
| Mar 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.00 | $3.10 | +3.3% | +10.0% | +3.3% | -0.9% | +0.9% | -4.4% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.96 | $3.00 | +1.4% | +0.7% | -0.3% | -0.7% | +1.7% | +10.0% |
| Sep 8 | Needham | Maintains | Buy → Buy | — | $1.43 | $1.42 | -0.7% | -1.4% | -2.1% | +1.4% | +2.9% | +11.1% |
| Sep 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.43 | $1.42 | -0.7% | -1.4% | -2.1% | +1.4% | +2.9% | +11.1% |
| Aug 23 | Needham | Maintains | Buy → Buy | — | $1.24 | $1.35 | +8.9% | +12.9% | +0.0% | +14.3% | +4.4% | -12.6% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $1.05 | $1.15 | +9.5% | +9.5% | +7.8% | +8.9% | -1.5% | -6.0% |
| May 26 | Needham | Maintains | Buy → Buy | — | $1.06 | $1.08 | +1.9% | +0.9% | -9.1% | +3.9% | +0.0% | +5.0% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $1.05 | $1.08 | +2.9% | -5.7% | +5.1% | +7.7% | +9.8% | -2.4% |
| Mar 30 | Needham | Maintains | Buy → Buy | — | $0.74 | $0.73 | -1.4% | -4.0% | -0.5% | +11.3% | +1.2% | +4.3% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $0.77 | $0.79 | +2.9% | +1.5% | +4.0% | -7.8% | +5.9% | -4.3% |
| Aug 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.15 | $1.23 | +7.0% | +17.4% | -3.7% | -7.7% | -1.7% | -0.8% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $0.57 | $0.57 | +0.0% | -2.8% | +12.8% | +2.4% | +7.8% | -4.8% |
| May 5 | BTIG | Maintains | Buy → Buy | — | $3.49 | $3.66 | +4.9% | -1.1% | -4.3% | +2.1% | -7.4% | +4.8% |
| Apr 5 | Needham | Maintains | Buy → Buy | — | $3.38 | $3.68 | +8.9% | +10.9% | +3.2% | +3.1% | +1.0% | +1.2% |
No insider trades available.
Data updated apr 26, 2026 1:13pm
· Source: massive.com